Athenex Inc

Athenex Inc is an international biotechnology and pharmaceutical company primarily engaged in the discovery, development, and commercialisation of a range of novel therapies for the treatment of various types of cancer. Headquartered in Buffalo, New York, the firm was established in 2003 and operates worldwide through three distinct segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The firm has various products in its pipeline at every research stage, from pre-clinical to phase 3. These therapies are aimed at the treatment of breast cancer, gastric cancer, solid tumours, multiple tumours, neuroblastoma, hepatocellular carcinoma, and R/R lymphoma and leukaemia. The firm’s first commercialised product, Kilsyri, aimed at treating actinic keratosis, is now FDA approved and has been brought to market under licence by Almirall. Operating via its Global Supply Chain platform, Athenex is engaged in the supply of active pharmaceutical ingredients (APIs) to clinical and commercial enterprises. Areas that the company focuses on include cell therapy, orascovery, and arginine deprivation therapy. In 2021, the firm announced an exclusive license agreement with the National Cancer Institute to develop autologous and allogenic cell therapies, utilising T cell receptors to target solid tumours. The firm trades on the NASDAQ under the ticker ATNX. Explore ATNX share prices and other stocks on eToro.